Facebook Pixel

Niacin More Effective Than Zetia In Dealing With Atherosclerosis

By HERWriter
Rate This

Niacin had better results in slowing down the progression of atherosclerosis than ezetimibe, or Zetia, in the ARBITER 6-HALTS trial, according to Peggy Peck, Executive Editor of MedPage Today.

Niacin as we are most familiar with it, is Vitamin B3. The niacin used for the trial was extended-release niacin or Niaspan.

Dr. Allen J. Taylor of the Walter Reed Army Medical Center, principal investigator of the trial, observed that niacin did a better job on the artery wall, and was the clear preference for add-on therapy.

"Although ezetimibe significantly reduced LDL by 19.2%, to an average of 66 mg/dL, the 'greater reductions in LDL cholesterol level in association with ezetimibe were significantly associated with an increase in carotid intima-media thickness,' according to a post hoc analysis conducted by Taylor and colleagues."

Niacin was also less likely to precipitate cardiac problems than ezetimibe.

Dr. W. Douglas Weaver, past president of the American College of Cardiology deemed niacin to be "an effective, but underutilized drug."


Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy

We value and respect our HERWriters' experiences, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice, although we hope you can gain knowledge from their insight.


Get Email Updates

Atherosclerosis Guide

Have a question? We're here to help. Ask the Community.


Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!